Table 3.
Bayesian NMA estimates of probability of superiority (P) and odds ratio (OR)
| Treatment | All-cause mortality | Clinical cure | Microbiological eradication | |||
|---|---|---|---|---|---|---|
| P % | OR (95% CrI) | P % | OR (95% CrI) | P % | OR (95% CrI) | |
| SUL | 98.1* | 0.27 (0.06–0.91) | 80.4 | 1.45 (0.62–3.48) | 98.9* | 4.82 (1.22–25.83) |
| IH COL + IV COL | 92.1 | 0.80 (0.58–1.10) | 99.9* | 1.67 (1.20–2.29) | 90.4 | 1.28 (0.88–1.88) |
| FOS + IV COL | 85.3 | 0.64 (0.28–1.45) | 66.3 | 1.20 (0.52–2.72) | 99.8* | 15.2 (2.27–428.6) |
| HD SUL | 74.5 | 0.56 (0.09–3.17) | 70.1 | 1.54 (0.32–8.63) | 38.3 | 0.79 (0.15–3.99) |
| HD TIG | 65.1 | 0.81 (0.25–2.53) | 91.8 | 2.48 (0.70–8.89) | 36.4 | 0.77 (0.19–3.30) |
| RIF + IV COL | 59.7 | 0.94 (0.56–1.54) | 78.1 | 1.63 (0.48–5.54) | 99.4* | 1.88 (1.14–3.13) |
| IH COL | 39.8 | 1.33 (0.12–13.87) | NA | NA | 55.9 | 1.22 (0.09–19.93) |
| GLY + IV COL | 35.3 | 1.13 (0.58–2.20) | 14.9 | 0.55 (0.17–1.65) | 21.6 | 0.62 (0.18–2.04) |
| TIG + IH COL | 31.3 | 1.47 (0.26–8.32) | NA | NA | 56.9 | 1.18 (0.18–7.40) |
| CAR + IV COL | 21.1 | 1.58 (0.49–5.52) | 14.2 | 0.50 (0.12–1.78) | 78.1 | 1.57 (0.50–5.45) |
| CAR + IH COL | 16.7 | 1.94 (0.48–8.19) | 9.9 | 0.38 (0.08–1.64) | 76.5 | 1.65 (0.42–7.06) |
| SUL + IH COL | 14.2 | 2.32 (0.43–12.63) | NA | NA | 90.4 | 3.37 (0.54–20.94) |
| SUL + IV COL | 7.0 | 2.58 (0.71–9.88) | 10.1 | 0.40 (0.09–1.60) | 73.3 | 1.51 (0.42–5.75) |
| TIG | 1.0* | 1.75 (1.09–2.81) | 38.7 | 0.89 (0.43–1.88) | 1.7* | 0.40 (0.16–0.94) |
Abbreviations: CAR carbapenem (imipenem or meropenem), COL colistin, CrI credible interval, FOS fosfomycin, GLY glycopeptide (vancomycin or teicoplanin), HD high-dose, IH inhaled, IV intravenous, NA not available, RIF rifampin, SUL sulbactam, TIG tigecycline
*P > 97.5% and P < 2.5%, statistically significant superiority and inferiority, respectively